Showing 5421-5430 of 10417 results for "".
- Allergan Reiterates its Belief that Valeant's Business Model is Unsustainablehttps://practicaldermatology.com/news/20140616-allergan_reiterates_its_belief_that_valeants_business_model_is_unsustainable/2459204/Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company") today reiterated the Company's concern regarding Valeant Pharmaceuticals International, Inc.'s ("Valeant") unsustainable business model, which relies on serial acquisitions and cost reductions, as opposed to top-line revenue growth and operati
- Presentation: PV-10 decreases Melanoma Cells in Tumors and Boosts T-Cellshttps://practicaldermatology.com/news/20140407-presentation_pv-10_decreases_melanoma_cells_in_tumors_and_boosts_t-cells/2459277/Treatment with Provectus Biopharmaceuticals, Inc.'s PV-10 produces a significant decrease in melanoma cells in tumors 7-14 days after treatment, new data show. The data were presented by researchers at the Moffitt Cancer Center at the American Association for Cancer Research Annual Meeting in Sa
- Data for PV-10 in Melanoma to be Presented at European Cancer Congresshttps://practicaldermatology.com/news/20130913-data_for_pv-10_in_melanoma_to_be_presented_at_european_cancer_congress/2459461/Analysis of data from Provectus Pharmaceuticals, Inc.'s completed Phase 2 study of intralesional PV-10 in metastatic melanoma will be presented at the upcoming European Cancer Congress (ECCO 17- ESMO-38 - ESTRO 32), taking place September 27 through
- Colorescience Expands Executive Teamhttps://practicaldermatology.com/news/20130531-colorescience_expands_executive_team/2459526/Colorescience appointed former SkinMedica CEO, Mary Fisher, who joins the brand in the same capacity. She will also serve on the Company's Board of Directors, which is chaired by David Hale of Hale BioPharma Ventures, LLC. Josie Juncal, Chief Commercial Officer for
- Merz Makes Offer for Obagihttps://practicaldermatology.com/news/20130402-merz_makes_offer_for_obagi/2459576/With an unexpected $383.5 million bid, Merz Pharma Group formally proposed to acquire Obagi Medical Products, outdoing rival Valeant's bid for Obagi announced late last month and reported in yesterday's edition of DermWire. Merz sent a letter to Obagi Medical Products Inc.'s board offering to buy al
- MBA Aesthetics Course Finalizes Facultyhttps://practicaldermatology.com/news/20121017-mba_aesthetics_course_finalizes_faculty/2459703/“Mastering the Business of Aesthetics,” a one-day course taking place on October 27, will offer attendees insight on various clinical and financial elements of aesthetics practice. The faculty includes Paul S. Nassif, MD, FACS, Melanie Palm, MD, MBA, Nissan Pilest, MD, Robert James Troell, MD, FASC,
- La Roche-Posay Awards Two Researchershttps://practicaldermatology.com/news/20120514-la_roche-posay_awards_two_researchers/2459803/At its seventh annual North American Foundation Research Awards, La Roche-Posay honored winners Sarina B. Elmariah, MD, PhD and Marie S. Tuttle, MD. Both researchers received a $10,000 grant to continue dermatological research and were honored at t
- Baricitinib, Ritlecitinib, and Deuruxolitinib Demonstrate Efficacy in Severe AAhttps://practicaldermatology.com/news/baricitinib-ritlecitinib-and-deuruxolitinib-demonstrate-efficacy-in-severe-aa/2485957/An analysis of clinical trials reports that Janus kinase (JAK) inhibitors shows significant efficacy and manageable safety profiles in treating severe alopecia areata (AA). Alopecia areata (AA) is an autoimmune disorder charac
- Diclofenac, Silymarin Show Promise for Preventing Chemotherapy-Induced Hand-Foot Syndrome: Meta-analysishttps://practicaldermatology.com/news/diclofenac-silymarin-show-promise-for-preventing-chemotherapy-induced-hand-foot-syndrome-meta-analysis/2485939/Diclofenac and topical silymarin reduced the risk of grade 2 or higher chemotherapy-induced hand-foot syndrome (HFS), according to a new meta-analysis of randomized clinical trials evaluating pharmacologic preventive strategies.
- Study: Tumor Location and Histologic Features Linked to Melanoma Recurrencehttps://practicaldermatology.com/news/study-tumor-location-and-histologic-features-linked-to-melanoma-recurrence/2485922/In patients with stage I–II melanoma, tumor location and histopathologic features were linked with recurrence risk beyond traditional factors such as ulceration and tumor thickness, according to a new study. Investigators exa